DGX PE Ratio & Valuation,Is DGX Overvalued — Intellectia
DGX Relative Valuation
DGX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, DGX is overvalued; if below, it's undervalued.
Historical Valuation
Quest Diagnostics Inc(DGX) is now in theFairzone, suggesting that its currentforward PEratio of18.05is consideredFairlycompared with the five-year average of15.54.The fair price ofQuest Diagnostics Inc(DGX)is between152.27to185.55according to relative valuation methord.
Relative Value
Fair Zone
152.27-185.55
Current Price：178.66
Fair
18.05
PE
1Y
3Y
5Y
Trailing
Forward
11.75
EV/EBITDA
Quest Diagnostics Inc. (DGX) has a current EV/EBITDA of 11.75. The 5-year average EV/EBITDA is 10.75. The thresholds are as follows: Strongly Undervalued below 8.50, Undervalued between 8.50 and 9.63, Fairly Valued between 11.88 and 9.63, Overvalued between 11.88 and 13.00, and Strongly Overvalued above 13.00. The current Forward EV/EBITDA of 11.75 falls within the Historic Trend Line -Fairly Valued range.
14.69
EV/EBIT
Quest Diagnostics Inc. (DGX) has a current EV/EBIT of 14.69. The 5-year average EV/EBIT is 13.18. The thresholds are as follows: Strongly Undervalued below 10.24, Undervalued between 10.24 and 11.71, Fairly Valued between 14.65 and 11.71, Overvalued between 14.65 and 16.12, and Strongly Overvalued above 16.12. The current Forward EV/EBIT of 14.69 falls within the Overvalued range.
1.80
PS
Quest Diagnostics Inc. (DGX) has a current PS of 1.80. The 5-year average PS is 1.72. The thresholds are as follows: Strongly Undervalued below 1.43, Undervalued between 1.43 and 1.58, Fairly Valued between 1.87 and 1.58, Overvalued between 1.87 and 2.01, and Strongly Overvalued above 2.01. The current Forward PS of 1.80 falls within the Historic Trend Line -Fairly Valued range.
12.23
P/OCF
Quest Diagnostics Inc. (DGX) has a current P/OCF of 12.23. The 5-year average P/OCF is 10.96. The thresholds are as follows: Strongly Undervalued below 8.17, Undervalued between 8.17 and 9.56, Fairly Valued between 12.35 and 9.56, Overvalued between 12.35 and 13.74, and Strongly Overvalued above 13.74. The current Forward P/OCF of 12.23 falls within the Historic Trend Line -Fairly Valued range.
17.30
P/FCF
Quest Diagnostics Inc. (DGX) has a current P/FCF of 17.30. The 5-year average P/FCF is 15.27. The thresholds are as follows: Strongly Undervalued below 10.58, Undervalued between 10.58 and 12.93, Fairly Valued between 17.61 and 12.93, Overvalued between 17.61 and 19.96, and Strongly Overvalued above 19.96. The current Forward P/FCF of 17.30 falls within the Historic Trend Line -Fairly Valued range.
Quest Diagnostics Inc (DGX) has a current Price-to-Book (P/B) ratio of 2.82. Compared to its 3-year average P/B ratio of 2.56 , the current P/B ratio is approximately 10.17% higher. Relative to its 5-year average P/B ratio of 2.58, the current P/B ratio is about 9.00% higher. Quest Diagnostics Inc (DGX) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 5.88%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 7.78% , the current FCF yield is about -100.00% lower.
2.82
P/B
Median3y
2.56
Median5y
2.58
6.86
FCF Yield
Median3y
5.88
Median5y
7.78
Competitors Valuation Multiple
The average P/S ratio for DGX's competitors is 0.29, providing a benchmark for relative valuation. Quest Diagnostics Inc Corp (DGX) exhibits a P/S ratio of , which is -100% above the industry average. Given its robust revenue growth of 13.18%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of DGX increased by 22.04% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 2.49B to 2.82B.
The secondary factor is the P/E Change, contributed 12.32%to the performance.
Overall, the performance of DGX in the past 1 year is driven by Revenue Growth. Which is more sustainable.
Is Quest Diagnostics Inc (DGX) currently overvalued or undervalued?
Quest Diagnostics Inc(DGX)is now in theFairzone, suggesting that its currentforward PEratio of 18.05is consideredFairlycompared with the five-year average of15.54.The fair price of Quest Diagnostics Inc(DGX)is between152.27to185.55according to relative valuation methord.
What is Quest Diagnostics Inc (DGX) fair value?
DGX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Quest Diagnostics Inc (DGX) is between 152.27to185.55 according to relative valuation methord.
How does DGX's valuation metrics compare to the industry average?
The average P/S ratio for DGX's competitors is 0.29, providing a benchmark for relative valuation. Quest Diagnostics Inc Corp (DGX) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of 13.18%, this premium appears unsustainable.
What is the current P/B ratio for Quest Diagnostics Inc (DGX) as of Dec 16 2025?
As of Dec 16 2025, Quest Diagnostics Inc (DGX) has a P/B ratio of 2.82. This indicates that the market values DGX at 2.82 times its book value.
What is the current FCF Yield for Quest Diagnostics Inc (DGX) as of Dec 16 2025?
As of Dec 16 2025, Quest Diagnostics Inc (DGX) has a FCF Yield of 0.00%. This means that for every dollar of Quest Diagnostics Inc’s market capitalization, the company generates 0.00 cents in free cash flow.
What is the current Forward P/E ratio for Quest Diagnostics Inc (DGX) as of Dec 16 2025?
As of Dec 16 2025, Quest Diagnostics Inc (DGX) has a Forward P/E ratio of 18.05. This means the market is willing to pay $18.05 for every dollar of Quest Diagnostics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Quest Diagnostics Inc (DGX) as of Dec 16 2025?
As of Dec 16 2025, Quest Diagnostics Inc (DGX) has a Forward P/S ratio of 0.00. This means the market is valuing DGX at $0.00 for every dollar of expected revenue over the next 12 months.
